Small, non-peptide C5a receptor antagonists: Part 1

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 20, 2008, Pages 5601-5604

  Blagg, Julian ^a   Mowbray, Charles ^a   Pryde, David C ^a   Salmon, Gary ^a   Schmid, Esther ^a   Fairman, David ^a   Beaumont, Kevin ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Antagonist; C5a receptor; Complement; Inflammation

Indexed keywords

COMPLEMENT COMPONENT 5A RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C5A RECEPTOR; CP 289503; CP 447697; UNCLASSIFIED DRUG;

ARTICLE; DRUG POTENCY; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; NONHUMAN; PHYSICAL CHEMISTRY; RAT; REACTION OPTIMIZATION; RECEPTOR BINDING;

ADMINISTRATION, ORAL; BUFFERS; CHEMISTRY, PHARMACEUTICAL; COMPLEMENT C5A; DRUG DESIGN; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; INHIBITORY CONCENTRATION 50; MICROSOMES, LIVER; MODELS, CHEMICAL; PEPTIDES; PIPERIDINES; PROTEIN BINDING;

EID: 53349163281     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.08.106     Document Type: Article

References (24)

1. Makrides S.C. Pharmacol. Rev. 50 (1998) 59
2. Gerard C., and Gerard P.N. Annu. Rev. Immunol. 12 (1994) 775
3. Tempero R.M., Hollingsworth M.A., and Burdick E.T. Immunology 158 (1996) 1377
4. March D.R., Proctor L.M., Stoermer M.J., Sbaglia R., Abbenante G., Reid R.C., Woodruff T.M., Wadi K., Paczkowski N., Tyndall J.D.A., Taylor S.M., and Fairlie D.P. Mol. Pharmacol. 65 (2004) 868
5. Finch A.M., Wong A.K., Paczkowski N.J., Wadi S.K., Craik D.J., Fairlie D.P., and Taylor S.M. J. Med. Chem. 42 (1999) 1965
6. Merck and Co., US Patent 5614370, 1997.
7. For reviews of the area see:. Taylor S.M., and Fairlie D.P. Exp. Opin. Ther. Pat. 10 (2000) 449
8. Allegretti M., Moriconi A., Beccari A.R., Bitondo R.D., Bizzarri C., Bertini R., and Colotta F. Curr. Med. Chem. 12 (2005) 217
9. Hutchison A.J., and Krause J.E. Ann. Rep. Med. Chem. 39 (2004) 139
10. de Laszlo S.E., Allen E.E., Li B., Ondeyka D., Rivero R., Malkawitz L., Molineaux C., Siciliano S.J., Springer M.S., Greenlee W.J., and Mantlo N.B. Bioorg. Med. Chem. Lett. 7 (1997) 213
11. Lanza T.J., Durette P.L., Rollins T., Siciliano S.J., Cianciarulo D.N., Kobayashi S.V., Caldwell C.J., Springer M.S., and Hagmann W.K. J. Med. Chem. 35 (1992) 252
12. Astles P.C., Brown T.J., Cox P., Halley F., Lockey P.M., McCarthy C., McLay I.M., Majid T.N., Morley A.D., Porter B., Ratcliffe A.J., and Walsh R.J.A. Bioorg. Med. Chem. Lett. 7 (1997) 907
13. Welfide Corp. WO Patent 0222556, 2002.
14. Neurogen Corp., WO Patent 0251414, 2002; WO Patent 082829, 2003.
15. Sumichika H., Sakata K., Sato N., Takeshita S., Ishibuchi S., Nakamura M., Kamahori T., Ehara S., Itoh K., Ohtsuka T., Ohbora T., Mishina T., Komatsu H., and Naka Y. J. Biol. Chem. 277 (2002) 49403
16. Barbay J.K., Gong Y., Buntinx M., Li J., Claes C., Hornby P.J., Lommen G.V., Van Wauwe J., and He W. Bioorg. Med. Chem. Lett. 18 (2008) 2544
17. Chemocentryx Inc. WO Patent 07051062, 2007.
18. Jerini AG, WO06128670, 2006.
19. Details of this work will be reported elsewhere.
20. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Deliv. Rev. 23 (1997) 3
21. Treiber A., Dansette P.M., Amri H.E., Girault J.-P., Ginderow D., Mornon J.-P., and Mansuy D. J. Am. Chem. Soc. 119 (1997) 1565
22. Hydride reduction of cyclohexanones forms predominantly trans alcohols, while larger nucleophiles favour cis. Isomers were separable by chromatography.
23. 125I-labelled r-hC5a (NEN) to measure bound radioligand.
24. Neutrophil degranulation was measured in cytochalasin B-primed isolated human neutrophils at 37 °C by quantification of released elastase by cleavage of the chromogenic MeOSuc-Ala-Ala-Pro-Val-pNA. C5aR antagonists were pre-incubated with neutrophils for 5 min at 37 °C prior to a 1 nM r-hC5a (Sigma) challenge.